100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Trading Comps Modeling | Wall Street Prep Exam $13.49   Add to cart

Exam (elaborations)

Trading Comps Modeling | Wall Street Prep Exam

 23 views  0 purchase
  • Course
  • Wall Street Prep
  • Institution
  • Wall Street Prep

Trading Comps Modeling | Wall Street Prep Exam Get your certification with this questions and Answers.

Preview 2 out of 6  pages

  • September 26, 2024
  • 6
  • 2024/2025
  • Exam (elaborations)
  • Questions & answers
  • Wall Street Prep
  • Wall Street Prep
avatar-seller
Treypapers
] Back to Course I ] Exit to Learning Dashboard



Review: Trading Comps Modeling Exam


Question 1
The next two questions use data from Athenahealth financial tiling, which can be downloaded by clicking here. The next two questions will use
the following scenario:
It is July 4, 2017 and you are asked to perform a company profile for Athena health (ATHN), with a latest closing share price of $140.07. The
company's most recent earnings report was tor the tirst quarter 2017 tor the period ending 3/31/2017.

Calculate ATHN's LTM Non-GAAP operating profit. Use the company's own definition of Non-GAAP operating profit when arriving at your
calculations.

Hint: You only need the Q1 2017 and Q4 2016 press releases to answer this question.

26.6
27.4
130.1
132.3
154.3




Question 2


This question uses the same Athenahealth data as the previous question, which can be downloaded by clicking

here. This question uses the same scenario as the previous question, repeated below:

It is July 4, 2017 and you are asked to perform a company profile for Athena health (ATHN), with a latest closing share price of $140.07. The
company's most recent earnings report was for the first quarter 2017 for the period ending 3/31/2017.

Calculate ATHN's enterprise value.

Hint: You only need the Q1 2017 10Q and the 2016 10K to answer this question.

5,655.00
5,682.80
5,809.00
.823.45
5,915.70




Question 3

A Company has the same level of Operating Income for Q1 of two consecutive years. However, for the more recent Q1, levels of D&A
dropped.

When you compare the Company's most recent Q1 LTM EBIT and EBITDA to those of its last complete fiscal year, you would expect:

LTM EBIT to increase, LTM EBITDA to decrease
LTM EBIT to increase, LTM EBITDA to increase

, LTM EBIT to stay tlat, LTM EBITDA to stay tlat
LTM EBIT to stay flat, LTM EBITDA to increase
LTM EBIT to stay flat, LTM EBITDA to decrease



Question 4

Which of the following statements is most correct about building a comparable company analysis?

It is never appropriate to include the target company in the peer group.
Using the peer group's average multiple is preferable to using the peer group's median multiple when you suspect significant
outliers. When EBITDA forecasts are available, share price valuation using EV/next year EBITDA is always preferable to valuation using
EV/LTM EBITDA.
Comps analysis is preferable to the DCF for valuing the share price of public companies because the market is providing a clear valuation
signal.
Valuing the share Jlrice of a com11any based on the P/E of its 11eers is not as useful as valuing based on the EV/EBITDA of its 11eers
when the target and 11eer grou11 have widely differing leveragg,




Question 5

The next two questions use data from the "HealthRx Excel Worksheet", which can be downloaded by clicking

here. The next two questions will use the following scenario:

You are advising HealthRx on a potential sale of its business (a "sell side"). You have been assigned the task of performing a comparable
company analysis for HealthRx in order to present a reasonable valuation range for HealthRx. You have compiled all the relevant data in the
downloadable file given above.

Excluding HealthRx from the peer group, what is the per share equity value of HealthRx based on the average peer group LTM P/E ratio1

38.38
38.81
39.04
40.36
55.15




Question 6

This question uses the same data as the previous question, which can be downloaded by clicking here.

This question uses the same scenario as the previous question, repeated below:

You are advising HealthRx on a potential sale of its business (a "sell side"). You have been assigned the task of performing a
comparable company analysis for HealthRx in order to present a reasonable valuation for HealthRx. You have compiled all the relevant
data in the file we've given you above.

Including HealthRx in the peer group, what is the per-share equity value for HealthRx based on the peer group's median Year 1
EV/Revenue multiple?

142.08
145.81
151_65
X 152.27
156.04




Question 7


Which valuation multiple is most appropriate when a peer group includes companies with different depreciation methods and negative
EBITDA7

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Treypapers. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $13.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

79223 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$13.49
  • (0)
  Add to cart